{
    "organizations": [],
    "uuid": "c6f791cccc3f3b70111789753748328e7212838c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-citius-reports-progress-in-hemorro/brief-citius-reports-progress-in-hemorroid-treatment-program-idUSFWN1QO0DV",
    "ord_in_thread": 0,
    "title": "BRIEF-Citius Reports Progress In Hemorroid Treatment Program",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Citius Pharmaceuticals Inc:\n* CITIUS REPORTS PROGRESS IN HEMORROID TREATMENT PROGRAM * CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS\n* CITIUS PHARMACEUTICALS INC - NEW FORMULATION, CITI-002, WILL COMBINE LIDOCAINE WITH HIGHER POTENCY CORTICOSTEROID\n* CITIUS PHARMACEUTICALS INC - HELD A TYPE C MEETING WITH FDA TO DISCUSS RESULTS OF PHASE 2A STUDY\n* CITIUS PHARMACEUTICALS - MEETING WITH FDA ALSO TO OBTAIN ITS VIEW ON PLANS TO SUPPORT POTENTIAL FORMULATION CHANGE FOR PLANNED PHASE 2B STUDY\n* CITIUS PHARMACEUTICALS INC - REQUESTED FDAâ€™S FEEDBACK ON PHASE 2B STUDY DESIGN\n* CITIUS PHARMACEUTICALS - PRE-CLINICAL, CLINICAL DEVELOPMENT PROGRAMS FOR CITI-002 PLANNED TO BE SIMILAR TO THOSE OF CITI-001 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T21:24:00.000+02:00",
    "crawled": "2018-03-07T19:45:48.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "citius",
        "pharmaceutical",
        "inc",
        "citius",
        "report",
        "progress",
        "hemorroid",
        "treatment",
        "program",
        "citius",
        "pharmaceutical",
        "selecting",
        "higher",
        "potency",
        "corticosteroid",
        "topical",
        "formulation",
        "program",
        "treatment",
        "hemorrhoid",
        "citius",
        "pharmaceutical",
        "inc",
        "new",
        "formulation",
        "combine",
        "lidocaine",
        "higher",
        "potency",
        "corticosteroid",
        "citius",
        "pharmaceutical",
        "inc",
        "held",
        "type",
        "c",
        "meeting",
        "fda",
        "discus",
        "result",
        "phase",
        "2a",
        "study",
        "citius",
        "pharmaceutical",
        "meeting",
        "fda",
        "also",
        "obtain",
        "view",
        "plan",
        "support",
        "potential",
        "formulation",
        "change",
        "planned",
        "phase",
        "2b",
        "study",
        "citius",
        "pharmaceutical",
        "inc",
        "requested",
        "fda",
        "feedback",
        "phase",
        "2b",
        "study",
        "design",
        "citius",
        "pharmaceutical",
        "clinical",
        "development",
        "program",
        "planned",
        "similar",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}